Cardiovascular Research

Enrollment completed in trial for paclitaxel-eluting coronary stent system

Published in Biotech Business Week, March 28th, 2005

Angiotech Pharmaceuticals, Inc., (ANPI, ANP) corporate partner, Boston Scientific (BSC), announced that it has completed enrollment in its ATLAS clinical trial.

ATLAS is the first trial using Boston Scientific's new Liberte coronary stent as a platform for its paclitaxel-eluting coronary stent system. Taxus Liberte is the next generation to Boston Scientific's first paclitaxel-eluting coronary stent system, Taxus Express, which is the worldwide leader in the coronary stent market today.

The ATLAS trial is a global, multicenter pivotal study designed to support U.S. Food and Drug Administration approval of the Taxus Liberte stent system. It is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-03-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry